Price History
Piramal Pharma Solutions has entered into a partnership with Botanix, a skincare-focused company, for the development of pharmaceutical substances. This collaboration marks a significant step in the manufacturing and supply sector for Botanix's dermatology products.
Piramal Pharma passes US FDA inspection at their Telangana facility, receiving an Establishment Inspection Report (EIR). This signifies a successful closure of the assessment, ensuring quality compliance for their operations. The announcement serves to maintain transparency and strengthen their regulatory records.
Piramal Pharma received a Form 483 with three minor observations during an FDA inspection at their Sellersville facility (May 4-8, 2026). Fortunately, no data integrity concerns were identified in the report.
Today, shares of Piramal Pharmaceuticals reached their peak during trading, signifying a positive trend for investors.
Piramal Pharma anticipates a double-digit revenue increase, primarily from profitable overseas operations. The company projects continued robust growth leading up to FY27.
Piramal Pharma demonstrates resilience, showing significant progress in the fourth quarter, with an uptick in revenues and improved margins amidst industry challenges. This indicates the company's robust operational performance in the pharmaceutical sector.
Piramal Pharma is aiming for strong revenue growth in the fiscal year 2027, with projections pointing towards an early to mid-teen increase. To achieve this goal, the company plans to expand its manufacturing capacities while focusing on cost-effective production methods.
Piramal Pharma anticipates accelerated growth in EBITDA and PAT compared to revenue, signifying increased operational efficiency. This optimistic outlook comes as the company recovers from previous year's obstacles, according to their recent conference call update.
Piramal Pharma reported a 3% decline in revenue for FY26 compared to the previous year, totaling approximately INR 8,869 crores with Q4 showing stability. The company's EBITDA decreased by 28%, reaching INR 1,135 crores and margins dropped to 13%. A significant impairment of INR 176 crore was also noted.
The Nifty Pharma index experienced a 3% rise today, with notable gains from Piramal Pharma (up 9%) and Dr Reddy's Laboratories (up 8%). This increase is attributed to the success of Obeda launch by Dr Reddy's in the GLP-1 market and new API contracts secured by Piramal Pharma.
Piramal Pharma has broken its downward trend, as evidenced by the Relative Strength Index (RSI) surpassing 50. This development, coupled with increased trading volume and a series of higher lows, suggests a possible shift in momentum for the company.
Piramal Pharma's U.S. facility in Lexington has successfully passed an FDA inspection, as indicated by a clean Establishment Inspection Report (EIR) with a Validated Action Indicated (VAI). This marks the closure of the inspection process, as per SEBI regulations, and the report was submitted on the first business day following its receipt.
The potential US implementation of a 100% tariff on imported pharmaceuticals could pose a significant disruption for Indian contract development and manufacturing organizations (CDMOs) such as Piramal Pharma, Glenmark, and Sun Pharma. This could lead to market uncertainties for these key players in the pharma industry.
Adani Power, Cochin Shipyard, Hyundai Motor India, among others, will now be available for trading in the Futures & Options segment as of April 1. Conversely, HUDCO, Piramal Pharma, Tata Technologies, and Torrent Power have withdrawn from the F&O market, with differing stock lot sizes per company.
Piramal Pharma's subsidiary has secured Kenalog, a significant addition to their global generic medications portfolio, from Bristol-Myers Squibb. This expansion is expected to strengthen their presence in the US, Europe, and Asia-Pacific markets for complex hospital generics.